HomeIR & PRNotice & News
ABL Bio, Announces BCMAx4-1BB Bispecific Antibody Superb Efficacy Compared to Bispecific An...
ABL Bio, Announces BCMAx4-1BB Bispecific Antibody Superb Efficacy Compared to Bispecific Antibodies by Global Big Pharma - Celgene’s BCMAxCD3 Clinical Trial Data Attracts Attention from American Society of Hematology - ABL Bio’s BCMAx4-1BB Bispecific Antibody Expected to Show Better Efficacy and Stability Compared to Previous BCMAxCD3 Release Date: Dec. 10, 2019 (Exp.) After BCMAxCD3 by Celgene Corporation (“Celgene”) garnered attention from the American Society of Hematology, ABL Bio, Inc. (“ABL Bio”) has been the topic of conversation with its announcement of BCMAx4-1BB Bisepcific Antibody (BsAb) that combines CD3 with another immune modulation target 4-1BB. It is known that Celgene’s BCMAxCD3 BsAb CC-93269, which had entered its clinical trial this April, achieved 88.9% of overall response rate (ORR) including high stringent complete response/complete response (sCR/CR) rate of 44.4% after administering high dose (10 mg) to patients of late-stage multiple myeloma, a cancer that has no suitable drugs. Compared to Celgene’s BCMAxCD3 BsAb, ABL Bio’s BCMAx4-1BB BsAb has no cytokine release syndrome (CRS), which is prevalent in CD3. In addition, while CD3 activates only the T-cells among human immune cells, 4-1BB engages with not only T-cells but also natural killer (NK) cells, making it a platform that is expected to perform remarkably better in terms of efficacy. In the case of ABL Bio’s 4-1BB platform, it has been proven to be superior in terms of stability, as it has resolved the issue of liver toxicity. The superiority of ABL Bio’s BCMAx4-1BB BsAb is gaining attention also because its half-life is overwhelmingly longer than that of BiTE platform-based BCMAxCD3 by Amgen. For BCMA CAR-T, which was the hot topic in last year’s American Society of Hematology, there is the challenge of creating patient-specific therapeutics. In case of BsAb, however, it is in the spotlight because not only is it easy to administer but also has better market opportunity than CAR-T in terms of price. Expressing strong confidence in the company’s BCMAx4-1BB BsAb, Sang Hoon Lee, the founder and CEO of ABL Bio, said, “Our BCMAx4-1BB is currently in preclinical stage but once it enters the clinical trial, it is expected to show better efficacy than Celgene’s CC-93269, as well as superb data in terms of stability.” This BsAb is currently under joint research and development with ABL Bio’s partner company TRIGR in the US and Dt&SanoMedics in Korea. In January of next year at the JP Morgan conference, ABL Bio and global big pharmas will have serious discussions not only on ABL Bio’s multiple BsAb-based immuno-oncology but also ABL301, a BsAb for treating Parkinson’s Disease, which is combined with blood brain barrier (BBB) penetration platform. This event will be of great interest to the industry as ABL Bio is expected to release data on ABL301 in comparison with that of Roche’s BsAb-base
ABL Bio Announces Strategic Partnership with I-Mab Biopharma of China
ABL Bio Announces Strategic Partnership with I-Mab Biopharma of China- Joint Development of Three Bispecific Antibodies… Acquired Global License outside China - ABL Bio, a Korean Biotech with Industry’s Top-rated Core Technology in Bispecific Antibody and Antibody Drug Conjugate (ADC) Release Date: July 26, 2018 ABL Bio Corporation (“ABL Bio”) formed a strategic partnership with a Chinese biotech firm I-Mab Biopharma (“I-Mab”). With this partnership, ABL Bio will conduct joint research with I-Mab on three Bispecific Antibodies (BsAbs) that combine PD-L1 and an undisclosed material. Including the development costs, licenses in China, Korea, and other countries are expected to be shared under different configurations. In addition, ABL Bio acquired the exclusive global rights to another BsAb in regions excluding Greater China. BsAb shows superior efficacy to monoclonal antibody and due to its low side effects, it reduces pain and stress for the patient. For this reason, BsAb is expected to be the new leading immuno-oncology therapy. Sang Hoon Lee, the founder and CEO of ABL Bio, said, “We are able to develop the first-in-class and the best-in-class BsAb through the partnership with I-Mab, and also to speed up the process of the development of innovative immunotherapy.” He added, “With the strong synergy between the two firms, I expect this partnership to be an exemplary case in the global biotech industry.” CEO Jingwu Zang of I-Mab said, “I am excited to have joined with ABL Bio which has the world’s best technology in BsAb. We will do our best to develop the antibody that will lead the next-generation immuno-oncology therapy.” ABL Bio currently holds core technologies in BsAb and Antibody Drug Conjugate (ADC), the next-generation antibody therapeutics platforms in the area of targeted anti-cancer therapy, immuno-oncology, and Parkinson’s Disease. For the first time in Korea, it is currently in Phase 1 clinical trial of ‘ABL-001’, the first new candidate for BsAb. I-Mab is a leading biotech firm in developing new therapeutics and runs a highly efficient team of world-class research ability. The company is developing the industry’s best biological products in immuno-oncology and immuno-inflammation. It is also preparing to submit multiple IND (Investigational New Drug) applications in order to pursue additional clinical trials and further research in the US and China.
ABL Bio Adopts Novel Bispecific Antibody Platform and Two Types of Immuno-Oncology Targete...
ABL Bio Adopts Novel Bispecific Antibody PlatformandTwo Types of Immuno-Oncology Targeted Antibody...More Opportunities to DevelopNovel Immuno-Oncology Bispecific Antibody Therapeutics Date: Feb. 25, 2018 (exp.)- US$220.5 million License-in Agreement on WuXiBody TM Bispecific Antibody Platform and Two Types of NovelImmuno-Oncology Antibody Sequences- Strategic Partnership with WuXi Biologics, Increasing Novel Immuno-Oncology Bispecific Antibody PipelinesSpecific to Patients Unresponsive to Anti-Pd1 and PD-L1 TherapeuticsOn February 25, ABL Bio Corporation (“ABL Bio”) announced its license-in agreement with WuXi Biologics(“WuXi Bio”) for WuXiBody TM BsAb platform and two types of novel immuno-oncology antibody sequences forUS$220.5 million. ABL Bio will pay the upfront fee and milestone payments for the development of clinical trials,as well as regulatory and commercial milestone payments.With this agreement, ABL Bio will acquire exclusive rights to the research & development and commercializationof novel Bispecific Antibody (BsAb) that utilizes WuXi Bio’s BsAb platform. As the partner for WuXi Bio, ABL Biowill adopt candidates for novel immune checkpoint inhibitors that are overexpressed among non-responsivegroups to immuno-oncology therapeutics, previously represented by PD-1 and PD-L1. With such adoption, ABLBio will be able to expand its pipeline, a move that is expected to help the company step up as the leader in theglobal BsAb industry.ABL Bio has confirmed in vivo the synergy effect of the combination treatment with PD-1 and PD-L1 immuno-oncology therapy. With this result, the company will develop novel immune checkpoint inhibitor BsAb that willovercome the limits of previous PD-1 therapeutics.WuXiBody TM BsAb platform can assemble all the sequences of monoclonal antibodies into a dual specificstructure, while having low immunogenicity, long half-life in vitro, and superb stability. In addition, it is possible toefficiently and expediently resolve in about 18 months the process of Chemistry, Manufacturing, and Controls(CMC), which is a great challenge in the development of BsAb, thereby significantly lowering the production cost.This platform yields 16g/L with not less than 95% purity, making it the only few ‘best-in-class’ BsAb platform inthe world.Sang Hoon Lee, the founder and CEO of ABL Bio, said, “The reason for recent adoption of BsAb platforms bythe global big pharmas is that one BsAb platform cannot encompass all the targets.” Lee also said, “We decidedto make the adoption with the confidence that th